Cost-effectiveness considerations in the treatment of essential thrombocythemia

Robert Golub, Jared Adams, Sundeep Dave, Charles L. Bennett

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Factors that influence the choice of anagrelide, hydroxyurea, or interferon-alfa (IFN-α) for treatment of essential thrombocythemia include efficacy, toxicity, and cost. Anagrelide has the US Food and Drug Administration's approval to be used for treating patients with thrombocythemia secondary to chronic myeloproliferative disorders. In contrast, the use of IFN-α and hydroxyurea are considered "off-label." We performed an incremental cost-effectiveness analysis to compare anagrelide, hydroxyurea, and IFN-α for treating essential thrombocythemia, in terms of estimated impact on life expectancy. The case used for this analysis was of a 40-year-old man with essential thrombocythemia. Clinical assumptions were based on information obtained from nonrandomized clinical trials, and the economic assumptions were derived from information abstracted from observational studies. Lifelong treatment use of anagrelide versus hydroxyurea would cost approximately $72,000 per additional year of life gained, while the use of IFN-α was found to be both more costly and less effective than anagrelide. The results were very sensitive to the risk of leukemia caused by hydroxyurea, with an incremental cost-effectiveness of anagrelide compared with hydroxyurea of $156,969 per additional year of life gained if the lifetime leukemia risk drops from a baseline of.08 to.05. Given that many commonly used medical interventions cost in the range of $50,000 to $100,000 per year of life gained, and the generally poor outcome associated with treatment-related leukemia that can result from hydroxyurea, anagrelide could be considered a therapeutic alternative that is clinically effective at an acceptable cost.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalSeminars in Oncology
Issue number3
StatePublished - Jun 2002

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Cost-effectiveness considerations in the treatment of essential thrombocythemia'. Together they form a unique fingerprint.

Cite this